Patients with chronic myelogenous leukemia (CML) at the Postgraduate Institute of Medical Education and Research (PGIMER) in India have been successfully treated with the drug Imatinib mesylate, which is provided free of cost to those who cannot afford it. Some patients have been able to live without a relapse of cancer and have even stopped taking the medication. The PGI has 4,000 registered CML patients, with 40 of them now off medication. The institute also treats around 170 cases of blood cancer in children annually, with a cure rate of 60%-70%.
